And Biomarin just stopped development on their current DMD drug, so that leaves a potential extra piece of the pie for somebody. Their drug (and Sarepta's) was not going to compete directly (at least initially) with PTC, so that wouldn't have bothered PTC. It'll be interesting to see what the UK says in their next review. I don't think they are going to be able to take Ataluren away from people and that is only going to help PTC's case with the FDA.